OBJECTIVE: To determine whether selected clinicopathologic factors, including the extent of pathologic response to preoperative radiation and chemotherapy (RT +/- chemo), have an impact on long-term recurrence-free survival (RFS) in patients with locally advanced primary rectal cancer after optimal multimodality therapy. SUMMARY BACKGROUND DATA: Although complete pathologic response to preoperative RT +/- chemo has been detected in up to 30% of rectal cancers, its significance on long-term outcome has not been widely reported. Previous retrospective studies evaluating clinical outcome in patients with complete or near-complete pathologic response documented good prognosis in this population but were limited by median follow-up in the range of 2 to 3 years. METHODS: Sixty-nine patients with locally advanced (T(3-4) and/or N1) primary rectal cancer were prospectively identified. All were treated at one institution with preoperative RT to the pelvis (at least 4,500 cGy). Forty patients received concurrent preoperative 5-fluorouracil-based chemotherapy and 27 received both pre- and postoperative chemotherapy. Patients underwent resection 4 to 7 weeks after completion of RT. TNM stage, angiolymphatic or perineural invasion, and extent of response to preoperative RT +/- chemo were determined by pathologic evaluation. Adverse pathologic features were defined as the presence of angiolymphatic and/or perineural invasion. RFS at 5 years was determined by the Kaplan-Meier method. RESULTS: With a median follow-up of 69 months, 5-year RFS was 79%. RFS was significantly worse for patients with aggressive pathologic features and positive nodal status identified in the postirradiated surgical specimen. Risk ratios for RFS were 3.68 for the presence of aggressive pathologic features and 4.64 for node-positive rectal cancers. In patients with greater than 95% rectal cancer response to preoperative RT +/- chemo, only one patient has died as a consequence of cancer, another has died of an unrelated cause, and the remainder were free of disease with a minimum follow-up of 47 months. CONCLUSIONS: These data suggest that a marked response to preoperative RT +/- chemo may be associated with good long-term outcome but was not predictive of RFS. The presence of poor histopathologic features and positive nodal status are the most important prognostic indicators after neoadjuvant therapy.
OBJECTIVE: To determine whether selected clinicopathologic factors, including the extent of pathologic response to preoperative radiation and chemotherapy (RT +/- chemo), have an impact on long-term recurrence-free survival (RFS) in patients with locally advanced primary rectal cancer after optimal multimodality therapy. SUMMARY BACKGROUND DATA: Although complete pathologic response to preoperative RT +/- chemo has been detected in up to 30% of rectal cancers, its significance on long-term outcome has not been widely reported. Previous retrospective studies evaluating clinical outcome in patients with complete or near-complete pathologic response documented good prognosis in this population but were limited by median follow-up in the range of 2 to 3 years. METHODS: Sixty-nine patients with locally advanced (T(3-4) and/or N1) primary rectal cancer were prospectively identified. All were treated at one institution with preoperative RT to the pelvis (at least 4,500 cGy). Forty patients received concurrent preoperative 5-fluorouracil-based chemotherapy and 27 received both pre- and postoperative chemotherapy. Patients underwent resection 4 to 7 weeks after completion of RT. TNM stage, angiolymphatic or perineural invasion, and extent of response to preoperative RT +/- chemo were determined by pathologic evaluation. Adverse pathologic features were defined as the presence of angiolymphatic and/or perineural invasion. RFS at 5 years was determined by the Kaplan-Meier method. RESULTS: With a median follow-up of 69 months, 5-year RFS was 79%. RFS was significantly worse for patients with aggressive pathologic features and positive nodal status identified in the postirradiated surgical specimen. Risk ratios for RFS were 3.68 for the presence of aggressive pathologic features and 4.64 for node-positive rectal cancers. In patients with greater than 95% rectal cancer response to preoperative RT +/- chemo, only one patient has died as a consequence of cancer, another has died of an unrelated cause, and the remainder were free of disease with a minimum follow-up of 47 months. CONCLUSIONS: These data suggest that a marked response to preoperative RT +/- chemo may be associated with good long-term outcome but was not predictive of RFS. The presence of poor histopathologic features and positive nodal status are the most important prognostic indicators after neoadjuvant therapy.
Authors: B D Minsky; A M Cohen; N Kemeny; W E Enker; D P Kelsen; B Reichman; L Saltz; E R Sigurdson; J Frankel Journal: J Clin Oncol Date: 1992-08 Impact factor: 44.544
Authors: J F Bosset; V Magnin; P Maingon; G Mantion; E P Pelissier; M Mercier; G Chaillard; J C Horiot Journal: Int J Radiat Oncol Biol Phys Date: 2000-01-15 Impact factor: 7.038
Authors: S Pucciarelli; M L Friso; P Toppan; A Fornasiero; S Carnio; E Marchiori; M Lise Journal: Ann Surg Oncol Date: 2000 Jan-Feb Impact factor: 5.344
Authors: M I Saunders; S Dische; E J Grosch; D C Fermont; R F Ashford; E J Maher; A R Makepeace Journal: Int J Radiat Oncol Biol Phys Date: 1991-08 Impact factor: 7.038
Authors: P A Coucke; B Sartorelli; J F Cuttat; W Jeanneret; M Gillet; R O Mirimanoff Journal: Int J Radiat Oncol Biol Phys Date: 1995-04-30 Impact factor: 7.038
Authors: Ewelina Kluza; Esther D Rozeboom; Monique Maas; Milou Martens; Doenja M J Lambregts; Jos Slenter; Geerard L Beets; Regina G H Beets-Tan Journal: Eur Radiol Date: 2012-07-10 Impact factor: 5.315
Authors: Dermot T McDowell; Fraser M Smith; John V Reynolds; Stephen G Maher; Collette Adida; Paul Crotty; Eoin F Gaffney; Donal Hollywood; Brian Mehigan; Richard B Stephens; M J Kennedy Journal: Int J Colorectal Dis Date: 2009-07-11 Impact factor: 2.571
Authors: Tobias Leibold; Vanessa W Hui; Jinru Shia; Jeannine A Ruby; Elyn R Riedel; José G Guillem Journal: Am J Surg Date: 2014-04-13 Impact factor: 2.565
Authors: Mahshid Jalilian; Sidney Davis; Mohammadreza Mohebbi; Bhuvana Sugamaran; Ian W Porter; Stephen Bell; Satish K Warrier; Roger Wale Journal: J Gastrointest Oncol Date: 2016-08